HU203475B - Process for producing pharmaceutical compositions treating apoplexia cerebri containing tetrahydro-naphtalene-, benzindol- or pyrimidine derivatives of serotonin-antagonistic activity - Google Patents
Process for producing pharmaceutical compositions treating apoplexia cerebri containing tetrahydro-naphtalene-, benzindol- or pyrimidine derivatives of serotonin-antagonistic activityInfo
- Publication number
- HU203475B HU203475B HU894897A HU489789A HU203475B HU 203475 B HU203475 B HU 203475B HU 894897 A HU894897 A HU 894897A HU 489789 A HU489789 A HU 489789A HU 203475 B HU203475 B HU 203475B
- Authority
- HU
- Hungary
- Prior art keywords
- serotonin
- benzindol
- naphtalene
- pharmaceutical compositions
- antagonistic activity
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 102000017911 HTR1A Human genes 0.000 abstract 1
- 101150015707 HTR1A gene Proteins 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Instructional Devices (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3831888A DE3831888A1 (de) | 1988-09-20 | 1988-09-20 | Arzneimittel zur behandlung von apoplexia cerebri |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUT52699A HUT52699A (en) | 1990-08-28 |
| HU203475B true HU203475B (en) | 1991-08-28 |
Family
ID=6363313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU894897A HU203475B (en) | 1988-09-20 | 1989-09-20 | Process for producing pharmaceutical compositions treating apoplexia cerebri containing tetrahydro-naphtalene-, benzindol- or pyrimidine derivatives of serotonin-antagonistic activity |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US4988700A (hu) |
| EP (1) | EP0360077B1 (hu) |
| JP (1) | JP2669507B2 (hu) |
| KR (2) | KR0135307B1 (hu) |
| AT (1) | ATE91623T1 (hu) |
| AU (1) | AU619895B2 (hu) |
| CA (1) | CA1331139C (hu) |
| DE (2) | DE3831888A1 (hu) |
| DK (1) | DK175128B1 (hu) |
| ES (1) | ES2058426T3 (hu) |
| FI (1) | FI894404A (hu) |
| HU (1) | HU203475B (hu) |
| IE (1) | IE62697B1 (hu) |
| IL (1) | IL91660A (hu) |
| PH (1) | PH26920A (hu) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU9301856D0 (en) * | 1990-12-24 | 1993-09-28 | Merrell Dow Pharma | Application of glutarimide derivatives for treating depressive and maniacal diseases |
| DE4135473A1 (de) * | 1991-10-28 | 1993-04-29 | Bayer Ag | Triazaspirodecanon-methylchromane |
| DE4138756A1 (de) * | 1991-11-26 | 1993-05-27 | Troponwerke Gmbh & Co Kg | Kombination mit neuroprotektiver wirkung |
| CA2145182C (en) * | 1992-09-25 | 2001-09-18 | Jonathan A. Bard | Dna encoding human alpha 1 adrenergic receptors and uses thereof |
| WO1994009765A1 (en) * | 1992-10-23 | 1994-05-11 | New York University | Functional interactions between glial s-100b and central nervous system serotonergic neurons |
| WO1999062505A2 (en) | 1998-06-01 | 1999-12-09 | Ortho-Mcneil Pharmaceutical, Inc. | Method for treating neurodegenerative disorders |
| US7045519B2 (en) * | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| WO1999065897A1 (en) | 1998-06-19 | 1999-12-23 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| EP1100794A1 (en) | 1998-07-17 | 2001-05-23 | Synaptic Pharmaceutical Corporation | COMPOUNDS SPECIFIC FOR THE HUMAN $g(a) 1d? ADRENERGIC RECEPTOR AND USES THEREOF |
| US6242473B1 (en) * | 1999-01-08 | 2001-06-05 | Maxim Pharmaceuticals, Inc. | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| DE19900544A1 (de) * | 1999-01-11 | 2000-07-13 | Basf Ag | Verwendung von Verbindungen der Formel I zur Prophylaxe und Therapie der zerebralen Ischämie |
| US20040106623A1 (en) * | 1999-07-16 | 2004-06-03 | Synaptic Pharmaceutical Corporation | Compounds specific for the human alpha1d adrenergic receptor and uses thereof |
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| US8703772B2 (en) | 2001-09-25 | 2014-04-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US20040002500A1 (en) * | 2002-06-28 | 2004-01-01 | Fabre Kramer Pharmaceutical, Inc. | Methods for treating attention deficit disorder |
| US20040077996A1 (en) * | 2002-10-22 | 2004-04-22 | Jasperson Keith E. | Drug infusion system with multiple medications |
| KR20130136010A (ko) * | 2005-04-13 | 2013-12-11 | 네우렉슨 인코포레이티드 | Ｎｏｓ 저해 활성을 갖는 치환된 인돌 화합물 |
| JP5350219B2 (ja) * | 2006-04-13 | 2013-11-27 | ニューラクソン，インコーポレーテッド | Ｎｏｓ阻害活性を有する１，５および３，６−置換インドール化合物 |
| EP2220074A4 (en) * | 2007-11-16 | 2012-01-04 | Neuraxon Inc | 3,5-SUBSTITUTED INDOL COMPOUNDS WITH NOS AND NOREPINEPHRINE RECOVERY-HEMDERING EFFECT |
| WO2009064505A1 (en) * | 2007-11-16 | 2009-05-22 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for treating visceral pain |
| NZ586082A (en) * | 2007-11-16 | 2013-03-28 | Neuraxon Inc | Indole compounds and methods for treating visceral pain |
| KR102357405B1 (ko) | 2021-05-07 | 2022-02-09 | 정진구 | 호흡기 운동기구 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8810748D0 (en) * | 1988-05-06 | 1988-06-08 | Beecham Wuelfing Gmbh & Co Kg | Novel treatment |
-
1988
- 1988-09-20 DE DE3831888A patent/DE3831888A1/de not_active Withdrawn
-
1989
- 1989-09-06 PH PH39203A patent/PH26920A/en unknown
- 1989-09-07 AT AT89116496T patent/ATE91623T1/de not_active IP Right Cessation
- 1989-09-07 ES ES89116496T patent/ES2058426T3/es not_active Expired - Lifetime
- 1989-09-07 EP EP89116496A patent/EP0360077B1/de not_active Expired - Lifetime
- 1989-09-07 DE DE8989116496T patent/DE58904960D1/de not_active Expired - Fee Related
- 1989-09-14 US US07/407,161 patent/US4988700A/en not_active Expired - Lifetime
- 1989-09-15 IL IL91660A patent/IL91660A/xx not_active IP Right Cessation
- 1989-09-15 AU AU41456/89A patent/AU619895B2/en not_active Ceased
- 1989-09-18 CA CA000611736A patent/CA1331139C/en not_active Expired - Fee Related
- 1989-09-18 FI FI894404A patent/FI894404A/fi not_active Application Discontinuation
- 1989-09-19 DK DK198904616A patent/DK175128B1/da not_active IP Right Cessation
- 1989-09-19 KR KR1019890013434A patent/KR0135307B1/ko not_active IP Right Cessation
- 1989-09-19 IE IE299089A patent/IE62697B1/en not_active IP Right Cessation
- 1989-09-20 JP JP1242417A patent/JP2669507B2/ja not_active Expired - Fee Related
- 1989-09-20 HU HU894897A patent/HU203475B/hu not_active IP Right Cessation
-
1990
- 1990-09-10 US US07/579,414 patent/US5070102A/en not_active Expired - Lifetime
-
1991
- 1991-06-13 US US07/714,470 patent/US5155128A/en not_active Expired - Lifetime
-
1997
- 1997-11-20 KR KR1019970061360A patent/KR0146486B1/ko not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPH02121935A (ja) | 1990-05-09 |
| AU4145689A (en) | 1990-03-29 |
| IL91660A (en) | 1993-08-18 |
| IL91660A0 (hu) | 1990-04-29 |
| KR900004352A (ko) | 1990-04-12 |
| DE3831888A1 (de) | 1990-03-29 |
| US5070102A (en) | 1991-12-03 |
| AU619895B2 (en) | 1992-02-06 |
| US5155128A (en) | 1992-10-13 |
| DK175128B1 (da) | 2004-06-07 |
| US4988700A (en) | 1991-01-29 |
| IE892990L (en) | 1990-03-20 |
| DK461689A (da) | 1990-03-21 |
| EP0360077B1 (de) | 1993-07-21 |
| FI894404A0 (fi) | 1989-09-18 |
| IE62697B1 (en) | 1995-02-22 |
| CA1331139C (en) | 1994-08-02 |
| FI894404A (fi) | 1990-03-21 |
| KR0146486B1 (ko) | 1998-08-17 |
| PH26920A (en) | 1992-12-03 |
| EP0360077A3 (de) | 1992-03-11 |
| DE58904960D1 (de) | 1993-08-26 |
| JP2669507B2 (ja) | 1997-10-29 |
| HUT52699A (en) | 1990-08-28 |
| ES2058426T3 (es) | 1994-11-01 |
| DK461689D0 (da) | 1989-09-19 |
| EP0360077A2 (de) | 1990-03-28 |
| ATE91623T1 (de) | 1993-08-15 |
| KR0135307B1 (ko) | 1998-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU203475B (en) | Process for producing pharmaceutical compositions treating apoplexia cerebri containing tetrahydro-naphtalene-, benzindol- or pyrimidine derivatives of serotonin-antagonistic activity | |
| HUT50152A (en) | Process for production of derivatives of benzopiran and medical compositions containing them as active substance | |
| HUT47090A (en) | Process for producing new thiazol derivatives and pharmaceutical compositions of leukotrinen-antagonistic activity containing them as active components | |
| HUT47131A (en) | Process for producing steroid-5alpha-reductase inhibitors and pharmaceutical compositions comprising them as active ingredient | |
| HUT46710A (en) | Process for producing peptode derivatives and pharmaceutical compositions containing them as active components | |
| HUT45252A (en) | Process for producing imidazo-pyridine derivatives and pharmaceutical compositions containing them as active components | |
| UA19171A (uk) | Спосіб одержаhhя фіhілалкіламіhів або їх фармакологічhо прийhятhих солей | |
| HUT49494A (en) | Process for producing active component of pharmaceutical compositions | |
| IT1170214B (it) | Composizione farmaceutica per la cura delle arteriopatie periferiche | |
| HUT48251A (en) | Process for producing new xantin derivatives and pharmaceutical compositions containing them as active components | |
| HUT50194A (en) | Process for production of new derivatives of neplanocine and medical compositions containing them as active substance | |
| HUT45537A (en) | Process for producing delta-22 derivatives of ll-f 28249 compounds and pharmaceutical compositions containing them as active components, and insecticide compositions | |
| HUT48642A (en) | Process for producing amino-acid derivatives and pharmaceutical compositions containing them as active components | |
| HUT39437A (en) | Process for producing new morpholinol derivatives and pharmaceutical compositions containing them as active agents | |
| HUT39602A (en) | Process for producing pharmaceutical compositions of citostatic activity | |
| HUT50196A (en) | Process for production of neuroquinine a antagonists and medical compositions containing them as active substance | |
| NO952611L (no) | Derivater av benzoylekgonin, ekgonin og ekgonidin som medisiner | |
| DE3169890D1 (en) | Derivative of n-acetilcysteine having therapeutical activity, process for its preparation and related pharmaceutical compositions | |
| HUT51146A (en) | Process for production of healing compositions containing active substances of medicinal plants | |
| HUT48585A (en) | Process for production of perhydrobenz /c,d/ sulphonamids and medical preparatives containing these compounds as active substance | |
| HUT59827A (en) | Process for producing pharmaceutical compositions containing pafantagonistic thieno-triazolo-diazepines for treating heart diseases produced by diminished beta-receptor-stimulant | |
| HUT40630A (en) | Process for producing relative compounds of histarigin and pharmaceutical compounds containing them as active agents | |
| HUT49813A (en) | Process for producing pharmaceutical compositions containing gonadoliberine derivatives of citostatic activity | |
| HUT49282A (en) | Process for production of medical compositions containing derivatives of 4-aroil-imidasole-2-on | |
| HUT53115A (en) | Process for production of alpha-glukozitade inhibitors and medical compositions containing them as active substance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HPC4 | Succession in title of patentee |
Owner name: BAYER AKTIENGESELLSCHAFT, DE |
|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |